真菌来源的β-葡聚糖,一种葡萄糖多糖,已被证明在临床环境中具有免疫调节特性。研究表明,来自灵芝(俗称灵芝)的β-葡聚糖在这方面具有特别的前景,在实验室和体内设置。为了进一步研究灵芝β-葡聚糖在人类受试者中的疗效和安全性,一个随机的,双盲,安慰剂对照临床试验在18~55岁的健康成年志愿者中进行.参与者被指示每天自我管理干预措施或安慰剂,持续84天。在研究开始和结束时进行血液工作评估。试验结果表明,干预组受试者,谁接受了灵芝β-葡聚糖,在各种免疫细胞群体中表现出显著的增强,包括CD3+,CD4+,CD8+T淋巴细胞,与安慰剂组相比,CD4/CD8比值和自然杀伤细胞计数也有所改善。此外,干预组和安慰剂组之间的血清免疫球蛋白A水平和自然杀伤细胞毒性有统计学意义的差异.值得注意的是,该干预措施被认为是安全且耐受性良好的,两组中肾脏或肝功能标志物均无统计学意义的变化。总的来说,该研究为灵芝β-葡聚糖调节健康成人免疫反应的能力提供了证据,从而潜在地加强他们对机会性感染的防御。
Fungi-derived β-glucan, a type of glucopolysaccharide, has been shown to possess immune-modulatory properties in clinical settings. Studies have indicated that β-glucan derived from Ganoderma lucidum (commonly known as Reishi) holds particular promise in this regard, both in laboratory and in vivo settings. To further investigate the efficacy and safety of Reishi β-glucan in human subjects, a randomized, double-blinded, placebo-controlled clinical
trial was conducted among healthy adult volunteers aged 18 to 55. Participants were instructed to self-administer the interventions or placebos on a daily basis for 84 days, with bloodwork assessments conducted at the beginning and end of the
study. The results of the
trial showed that subjects in the intervention group, who received Reishi β-glucan, exhibited a significant enhancement in various immune cell populations, including CD3+, CD4+, CD8+ T-lymphocytes, as well as an improvement in the CD4/CD8 ratio and natural killer cell counts when compared to the placebo group. Additionally, a statistically significant difference was observed in serum immunoglobulin A levels and natural killer cell cytotoxicity between the intervention and placebo groups. Notably, the intervention was found to be safe and well tolerated, with no statistically significant changes observed in markers of kidney or liver function in either group. Overall, the
study provides evidence for the ability of Reishi β-glucan to modulate immune responses in healthy adults, thereby potentially bolstering their defense against opportunistic infections.